- Home
- YSG vs TECX Comparison
YSG vs TECX Comparison
Compare YSG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- TECX
- Stock Information
- Founded
- YSG 2016
- TECX 2019
- Country
- YSG China
- TECX United States
- Employees
- YSG N/A
- TECX N/A
- Industry
- YSG Package Goods/Cosmetics
- TECX
- Sector
- YSG Consumer Discretionary
- TECX
- Exchange
- YSG Nasdaq
- TECX Nasdaq
- Market Cap
- YSG 362.5M
- TECX 311.3M
- IPO Year
- YSG 2020
- TECX 2018
- Fundamental
- Price
- YSG $3.98
- TECX $17.02
- Analyst Decision
- YSG
- TECX Strong Buy
- Analyst Count
- YSG 0
- TECX 5
- Target Price
- YSG N/A
- TECX $77.75
- AVG Volume (30 Days)
- YSG 162.0K
- TECX 264.6K
- Earning Date
- YSG 05-21-2025
- TECX 05-24-2025
- Dividend Yield
- YSG N/A
- TECX N/A
- EPS Growth
- YSG N/A
- TECX N/A
- EPS
- YSG N/A
- TECX N/A
- Revenue
- YSG $464,908,550.00
- TECX N/A
- Revenue This Year
- YSG $16.55
- TECX N/A
- Revenue Next Year
- YSG $13.17
- TECX N/A
- P/E Ratio
- YSG N/A
- TECX N/A
- Revenue Growth
- YSG N/A
- TECX N/A
- 52 Week Low
- YSG $2.60
- TECX $1.40
- 52 Week High
- YSG $6.13
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- YSG 45.88
- TECX 39.69
- Support Level
- YSG $3.42
- TECX $15.96
- Resistance Level
- YSG $4.23
- TECX $18.49
- Average True Range (ATR)
- YSG 0.39
- TECX 1.67
- MACD
- YSG -0.08
- TECX 0.55
- Stochastic Oscillator
- YSG 32.00
- TECX 67.21
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.